Suppr超能文献

口服米多君治疗可加速 ICU 患者停止静脉血管加压素输注。

Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions.

机构信息

Department of Pharmacy, Massachusetts General Hospital, Boston, MA.

出版信息

J Crit Care. 2013 Oct;28(5):756-62. doi: 10.1016/j.jcrc.2013.05.021. Epub 2013 Jul 8.

Abstract

PURPOSE

Persistent low-level hypotension represents a barrier to discharging patients from the intensive care unit (ICU). Midodrine may be an effective adjunct to wean intravenous (IV) vasopressors and permit ICU discharge. We tested the hypothesis that midodrine, given to patients on IV vasopressors who otherwise met ICU discharge criteria, increased the magnitude of change in IV vasopressor rate.

MATERIALS AND METHODS

This was a prospective, observational study in 20 adult surgical ICU patients who met ICU discharge criteria except for an IV vasopressor requirement. We compared the change in phenylephrine equivalent rates during the day before midodrine to the change in phenylephrine equivalent rates after midodrine initiation and analyzed changes in total body fluid balance, heart rate, mean arterial pressure, and white blood cell count during this period.

RESULTS

Patients received 41.0±33.4 μg/min of phenylephrine equivalents and the change in IV vasopressor rate (slope) decreased significantly from -0.62 μg/min per hour of phenylephrine equivalents before midodrine to -2.20 μg/min per hour following the initiation of midodrine treatment (P=.012). Change in total body fluid balance, heart rate, mean arterial pressure, and white blood cell count did not correlate with change in IV vasopressor rate.

CONCLUSION

Midodrine treatment was associated with an increase in the magnitude of decline of the IV vasopressor rate. Oral midodrine may facilitate liberation of surgical ICU patients from an IV vasopressor infusion, and this may affect discharge readiness of patients from the ICU.

摘要

目的

持续的低血压水平是将患者从重症监护病房(ICU)中出院的障碍。米多君可能是一种有效的辅助药物,可以停止静脉(IV)血管加压素的输注,并允许患者从 ICU 出院。我们检验了这样一个假设,即在符合 ICU 出院标准但仍需要 IV 血管加压素治疗的患者中使用米多君,是否能增加 IV 血管加压素输注率的变化幅度。

材料与方法

这是一项前瞻性、观察性研究,纳入了 20 名符合 ICU 出院标准但需要 IV 血管加压素治疗的成年外科 ICU 患者。我们比较了米多君使用前后的去甲肾上腺素等效物输注率的变化,并分析了在此期间的总体液平衡、心率、平均动脉压和白细胞计数的变化。

结果

患者接受了 41.0±33.4μg/min 的去甲肾上腺素等效物治疗,IV 血管加压素输注率的变化(斜率)从米多君使用前的-0.62μg/min/小时显著下降至米多君使用后的-2.20μg/min/小时(P=.012)。总体液平衡、心率、平均动脉压和白细胞计数的变化与 IV 血管加压素输注率的变化无相关性。

结论

米多君治疗与 IV 血管加压素输注率下降幅度的增加有关。口服米多君可能有助于外科 ICU 患者停止 IV 血管加压素输注,这可能会影响 ICU 患者的出院准备情况。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验